tiprankstipranks
Advertisement
Advertisement

SLN Stock Latest News

Silence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
RatingsSilence Therapeutics Earns Buy Rating on Promising Divesiran Phase I Data and Best-in-Class Potential
2h ago
SLN
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
PremiumCompany Announcements
Silence Therapeutics Highlights Positive Divesiran Phase 1 SANRECO Data
8h ago
8K
SLN
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
PremiumThe Fly
Silence Therapeutics highlights follow-up data on divesiran at EHA 2026
9h ago
SLN
Silence Therapeutics Reaffirmed at Buy as Analyst Sees PV Program Driving Upside; $25 Price Target Maintained
PremiumRatings
Silence Therapeutics Reaffirmed at Buy as Analyst Sees PV Program Driving Upside; $25 Price Target Maintained
9d ago
SLN
Silence Therapeutics: Buy Rating Reiterated on Pipeline Catalysts and PV Potential; $25 Price Target Maintained
PremiumRatings
Silence Therapeutics: Buy Rating Reiterated on Pipeline Catalysts and PV Potential; $25 Price Target Maintained
13d ago
SLN
Buy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target
PremiumRatingsBuy Rating Reiterated on Silence Therapeutics as Advancing RNAi Pipeline and 2026 Catalysts Support Unchanged $75 Price Target
21d ago
SLN
Silence Therapeutics Establishes New At-The-Market Program
Premium
Company Announcements
Silence Therapeutics Establishes New At-The-Market Program
24d ago
8K
SLN
Silence Therapeutics files $300M ordinary shares offering
Premium
The Fly
Silence Therapeutics files $300M ordinary shares offering
24d ago
SLN
Silence Therapeutics price target lowered to $27 from $35 at Chardan
PremiumThe Fly
Silence Therapeutics price target lowered to $27 from $35 at Chardan
1M ago
SLN
Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year
PremiumThe Fly
Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year
1M ago
SLN
Silence Therapeutics: Pipeline Resilience and Upcoming Clinical Catalysts Support Buy Rating Despite AstraZeneca Exit
PremiumRatings
Silence Therapeutics: Pipeline Resilience and Upcoming Clinical Catalysts Support Buy Rating Despite AstraZeneca Exit
3M ago
SLN
Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results
PremiumCompany Announcements
Silence Therapeutics Updates Pipeline, Reports 2025 Financial Results
3M ago
8K
SLN
Silence Therapeutics Appoints CFO Rhonda Hellums to Board
PremiumCompany AnnouncementsSilence Therapeutics Appoints CFO Rhonda Hellums to Board
6M ago
8K
SLN
Silence Therapeutics Announces CEO Departure and Leadership Changes
Premium
Company Announcements
Silence Therapeutics Announces CEO Departure and Leadership Changes
6M ago
8K
SLN
Silence Therapeutics CEO Craig Tooman to end employment
Premium
The Fly
Silence Therapeutics CEO Craig Tooman to end employment
6M ago
SLN
Silence Therapeutics Reports Q3 2025 Financial Results
PremiumCompany Announcements
Silence Therapeutics Reports Q3 2025 Financial Results
7M ago
SLN
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
PremiumRatings
Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position
7M ago
SLN
Silence Therapeutics reports Q3 EPS (15c), consensus (21c)
PremiumThe Fly
Silence Therapeutics reports Q3 EPS (15c), consensus (21c)
7M ago
SLN
Silence Therapeutics Completes Enrollment for Phase 2 Study
PremiumCompany Announcements
Silence Therapeutics Completes Enrollment for Phase 2 Study
8M ago
8K
SLN
Silence Therapeutics completes patient enrollment in SANRECO
PremiumThe FlySilence Therapeutics completes patient enrollment in SANRECO
8M ago
SLN
Silence Therapeutics: Promising mRNAi GOLD Platform and Strategic Initiatives Drive Buy Rating
Premium
Ratings
Silence Therapeutics: Promising mRNAi GOLD Platform and Strategic Initiatives Drive Buy Rating
8M ago
SLN
Silence Therapeutics: Strong Growth Potential with Promising Clinical Advances and Strategic Collaborations
Premium
Ratings
Silence Therapeutics: Strong Growth Potential with Promising Clinical Advances and Strategic Collaborations
9M ago
SLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >